 recombin human alpha-interferon patient chronic non-a non-b hepat multicent trial franc multicent trial dose recombin human alpha-interferon efficaci patient chronic non-a non-b hepat sourc infect transfus patient intraven drug abus patient patient patient treatment treatment MU alpha-interferon time week wk forty-f patient posit antibodi viru treatment period mean serum alt level treatment group decreas signific MU group wk proport patient normal alt level similar MU group MU group control repeat liver biopsi specimen signific decreas sever histolog chang MU group MU group control respons alpha-interferon patient age gender sourc infect pretreat serum alt presenc anti-hepat viru cirrhosi treatment mean alt level treat group proport patient normal alt level wk MU group MU group conclus dose MU superior MU alpha-interferon time wk improv serum alt level histolog examin